Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon

No, a popular blood pressure medication does not increase heart failure risk, new research confirms

Dihydropyridines such as amlodipine have been the topic of some debate in recent months due to fears they lead to significant side effects. 

Impella Heart Pump Abiomed RECOVER IV RCT cardiogenic shock

FDA warns Abiomed about ‘significant violations’ related to its Impella heart pumps

The agency said Abiomed did not seek the necessary approvals for one Impella-related device and was slow to act on certain safety concerns. 

Thumbnail

Endotronix gains key approval from FDA, shares new heart failure data

The company can now begin the enrollment process for its PROACTIVE-HF 2 clinical trial, which will focus on treating patients with NYHA class II heart failure. 

CBD could be beneficial for some heart failure patients

The subcutaneous administration of CBD could make a significant impact on patient outcomes, according to new findings presented at the Heart Failure Society of America's annual meeting in Cleveland.

Patisiran, marketed under the name Onpattro

FDA chooses not to approve patisiran for treating ATTR cardiomyopathy

The announcement came just weeks after an FDA subcommittee voted in favor of approval. 

What is CKM syndrome? American Heart Association outlines how to identify and manage a dangerous new condition

The American Heart Association has developed an updated strategy for the prevention and management of cardiovascular disease. A newly defined health condition, cardiovascular-kidney-metabolic syndrome, sits at the center of that strategy. 

Artificial intelligence (AI) is being developed to help make cardiovascular clinical trials more efficient, lead to faster advances in patient care, and bring possible new treatments to heart patients more quickly. The major cardiac research center of Icahn School of Medicine at Mount Sinai announced today that it signed a memorandum of understanding with the Chiba Institute of Technology (CIT) to collaborate on using AI to enhance cardiovascular disease research.

Mount Sinai partners with the Chiba Institute of Technology on AI to transform cardiovascular research 

Agreement aims to use AI to help make cardiology clinical trials more efficient and lead to faster advances in patient care. 

AI artificial intelligence stethoscope doctor

FDA clears AI model for detecting signs of heart failure in ECGs

The advanced AI model, developed by Anumana with help from Mayo Clinic, could provide value as a screening tool for heart failure.

Displaying 145 - 152 of 1304

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.